Cargando…
Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial
BACKGROUND: Whether Helicobacter pylori eradication actually suppresses the development of metachronous gastric cancer (MGC) after endoscopic resection (ER) remains controversial. The aims of this study were to clarify (1) the molecular markers related to carcinogenesis in intestinal metaplasia (IM)...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716539/ https://www.ncbi.nlm.nih.gov/pubmed/26671747 http://dx.doi.org/10.1038/bjc.2015.418 |
_version_ | 1782410554596392960 |
---|---|
author | Kawanaka, Maki Watari, Jiro Kamiya, Noriko Yamasaki, Takahisa Kondo, Takashi Toyoshima, Fumihiko Ikehara, Hisatomo Tomita, Toshihiko Oshima, Tadayuki Fukui, Hirokazu Daimon, Takashi Das, Kiron M Miwa, Hiroto |
author_facet | Kawanaka, Maki Watari, Jiro Kamiya, Noriko Yamasaki, Takahisa Kondo, Takashi Toyoshima, Fumihiko Ikehara, Hisatomo Tomita, Toshihiko Oshima, Tadayuki Fukui, Hirokazu Daimon, Takashi Das, Kiron M Miwa, Hiroto |
author_sort | Kawanaka, Maki |
collection | PubMed |
description | BACKGROUND: Whether Helicobacter pylori eradication actually suppresses the development of metachronous gastric cancer (MGC) after endoscopic resection (ER) remains controversial. The aims of this study were to clarify (1) the molecular markers related to carcinogenesis in intestinal metaplasia (IM) by a cross-sectional study, and (2) the changes of those markers by an open-label, randomised controlled trial (RCT) of H. pylori treatment. METHODS: First, we evaluated microsatellite instability (MSI), the methylation status at hMLH1, CDKN2A and APC genes, and immunoreactivity using the monoclonal antibody (mAb) Das-1 in IM in the background mucosa of 131 patients who underwent ER for gastric neoplasia and 22 chronic gastritis cases (control). Next, we performed an RCT to evaluate the changes of MSI between the H. pylori-eradicated (n=19) and non-eradicated patients (n=17) at 1 year among the H. pylori-positive patients. RESULTS: Microsatellite instability and mAb Das-1 reactivity showed significantly higher incidences in both the H. pylori-positive and -negative patients compared with the control group, thus suggesting that MSI and mAb Das-1 reactivity are associated with gastric neoplasia (OR=5.06 for MSI; OR=2.51 for mAb Das-1 reactivity). The RCT showed that H. pylori eradication did not provide significant reversals of any molecular alterations including MSI (the primary end point) and other methylation statuses and mAb Das-1 reactivity (secondary end points). CONCLUSIONS: H. pylori eradication did not produce significant changes in the molecular alterations related to carcinogenesis, suggesting that H. pylori treatment may not prevent the development of MGC in background mucosa with IM. |
format | Online Article Text |
id | pubmed-4716539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47165392017-01-12 Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial Kawanaka, Maki Watari, Jiro Kamiya, Noriko Yamasaki, Takahisa Kondo, Takashi Toyoshima, Fumihiko Ikehara, Hisatomo Tomita, Toshihiko Oshima, Tadayuki Fukui, Hirokazu Daimon, Takashi Das, Kiron M Miwa, Hiroto Br J Cancer Clinical Study BACKGROUND: Whether Helicobacter pylori eradication actually suppresses the development of metachronous gastric cancer (MGC) after endoscopic resection (ER) remains controversial. The aims of this study were to clarify (1) the molecular markers related to carcinogenesis in intestinal metaplasia (IM) by a cross-sectional study, and (2) the changes of those markers by an open-label, randomised controlled trial (RCT) of H. pylori treatment. METHODS: First, we evaluated microsatellite instability (MSI), the methylation status at hMLH1, CDKN2A and APC genes, and immunoreactivity using the monoclonal antibody (mAb) Das-1 in IM in the background mucosa of 131 patients who underwent ER for gastric neoplasia and 22 chronic gastritis cases (control). Next, we performed an RCT to evaluate the changes of MSI between the H. pylori-eradicated (n=19) and non-eradicated patients (n=17) at 1 year among the H. pylori-positive patients. RESULTS: Microsatellite instability and mAb Das-1 reactivity showed significantly higher incidences in both the H. pylori-positive and -negative patients compared with the control group, thus suggesting that MSI and mAb Das-1 reactivity are associated with gastric neoplasia (OR=5.06 for MSI; OR=2.51 for mAb Das-1 reactivity). The RCT showed that H. pylori eradication did not provide significant reversals of any molecular alterations including MSI (the primary end point) and other methylation statuses and mAb Das-1 reactivity (secondary end points). CONCLUSIONS: H. pylori eradication did not produce significant changes in the molecular alterations related to carcinogenesis, suggesting that H. pylori treatment may not prevent the development of MGC in background mucosa with IM. Nature Publishing Group 2016-01-12 2015-12-15 /pmc/articles/PMC4716539/ /pubmed/26671747 http://dx.doi.org/10.1038/bjc.2015.418 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Clinical Study Kawanaka, Maki Watari, Jiro Kamiya, Noriko Yamasaki, Takahisa Kondo, Takashi Toyoshima, Fumihiko Ikehara, Hisatomo Tomita, Toshihiko Oshima, Tadayuki Fukui, Hirokazu Daimon, Takashi Das, Kiron M Miwa, Hiroto Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title | Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title_full | Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title_fullStr | Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title_full_unstemmed | Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title_short | Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
title_sort | effects of helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716539/ https://www.ncbi.nlm.nih.gov/pubmed/26671747 http://dx.doi.org/10.1038/bjc.2015.418 |
work_keys_str_mv | AT kawanakamaki effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT watarijiro effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT kamiyanoriko effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT yamasakitakahisa effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT kondotakashi effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT toyoshimafumihiko effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT ikeharahisatomo effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT tomitatoshihiko effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT oshimatadayuki effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT fukuihirokazu effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT daimontakashi effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT daskironm effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial AT miwahiroto effectsofhelicobacterpylorieradicationonthedevelopmentofmetachronousgastriccancerafterendoscopictreatmentanalysisofmolecularalterationsbyarandomisedcontrolledtrial |